Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $74.8 million.

  • Agios Pharmaceuticals' Total Current Liabilities fell 3741.62% to $74.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.8 million, marking a year-over-year decrease of 3741.62%. This contributed to the annual value of $81.2 million for FY2024, which is 1942.61% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Total Current Liabilities of $74.8 million as of Q3 2025, which was down 3741.62% from $70.4 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Total Current Liabilities ranged from a high of $119.5 million in Q3 2024 and a low of $45.1 million during Q1 2023
  • Moreover, its 5-year median value for Total Current Liabilities was $59.8 million (2021), whereas its average is $64.4 million.
  • In the last 5 years, Agios Pharmaceuticals' Total Current Liabilities plummeted by 5254.91% in 2022 and then surged by 10445.19% in 2024.
  • Over the past 5 years, Agios Pharmaceuticals' Total Current Liabilities (Quarter) stood at $59.8 million in 2021, then rose by 4.69% to $62.6 million in 2022, then grew by 8.5% to $68.0 million in 2023, then rose by 19.43% to $81.2 million in 2024, then fell by 7.88% to $74.8 million in 2025.
  • Its last three reported values are $74.8 million in Q3 2025, $70.4 million for Q2 2025, and $52.4 million during Q1 2025.